ThromboGenics Takes Its Time On Solo Launch Of Eye Drug Jetrea
This article was originally published in The Pink Sheet Daily
Having taken a conservative approach to its first commercial launch, ThromboGenics plans to roll out newly approved eye drug Jetrea (ocriplasmin) in January 2013. Company is now recruiting a sales force to target retinal specialists, who are already well aware of the new drug.
You may also be interested in...
Germany’s IQWiG has backed Novartis’ Jetrea for VMT, albeit with restricted indication, but knocked back Almirall’s Constella, citing study irrelevance.
The EMA has given the nod to Novartis subsidiary Alcon’s vitreomacular traction drug Jetrea and agreed to an indication extension for its Ilaris product to treat gouty arthritis. EMA’s Committee for Medicinal Products for Human Use also confirmed a recommendation to suspend the marketing authorizations of three Merck Sharp & Dohme products used to treat adults with dyslipidemia.
Novartis' ophthalmic unit Alcon will collaborate with Belgium's ThromboGenics on the marketing and future development of the vitreomacular adhesion therapy, ocriplasmin.